Patient characteristics
| Patient no. . | CLL/ SLL . | Bulky . | Binet stage . | Circulating count, cells/mm3 . | Treatments . | Active disease IWCLL 2008 criteria . | IgVH . | Mutations . |
|---|---|---|---|---|---|---|---|---|
| Blood samples from untreated patients | ||||||||
| BL01 | SLL | Yes | B | 3 300 | Untreated | No | Unmutated | tri12 |
| BL02 | CLL | Yes | B | 30 000 | Untreated | No | Unmutated | del(11q), del(13q), del(14q), complex karyotype |
| BL03 | CLL | Yes | B | 22 000 | Untreated | No | Unmutated | del(11q) |
| BL04 | CLL | No | A | 120 000 | Untreated | No | Mutated | t(14;18) |
| BL05 | CLL | No | A | 50 000 | Untreated | No | Mutated | Normal karyotype |
| BL06 | CLL | No | B | 45 000 | Untreated | No | Unmutated | tri12, del(6q), simple karyotype |
| BL07 | CLL | No | A | 106 000 | Untreated | Yes | Unmutated | del(13q) |
| BL08 | CLL | No | A | 130 000 | Untreated | No | Unmutated | Normal karyotype |
| BL09 | CLL | No | A | 21 000 | Untreated | No | Mutated | del(13q), tri12, tri19 |
| BL10 | CLL | No | B | 77 000 | Untreated | No | Mutated | Normal karyotype |
| BL11 | CLL | No | C | 79 860 | Untreated | Yes | Unmutated | t(3;8), del6q |
| BL12 | CLL | No | B | 65 710 | Untreated | No | Mutated | del13q, del11q |
| BL13 | CLL | No | A | 111 710 | Untreated | No | NA | NA |
| BL14 | CLL | No | C | 93 400 | Untreated | Yes | Unmutated | del1q, del6q, del13q |
| BL15 | CLL | Yes | C | 52 000 | Untreated | Yes | Unmutated | Normal karyotype |
| BL16 | CLL | Yes | C | 141 000 | Untreated | Yes | Mutated | del(13q) |
| BL17 | CLL | Yes | B | 82 700 | Untreated | No | Unmutated | del(17p), tri12, del(13q) |
| BL18 | CLL | Yes | C | 177 000 | Untreated | Yes | Mutated | NA |
| BL19 | CLL | Yes | C | 40 000 | Untreated | Yes | Mutated | del(13q) |
| BL20 | CLL | Yes | C | 140 000 | Untreated | Yes | Mutated | del(13q), del(17p), complex karyotype |
| BL21 | CLL | Yes | B | 80 000 | Untreated | No | Mutated | del(11q) |
| BL22 | CLL | Yes | B | 76 300 | Untreated | No | Mutated | tri12 |
| BL23 | CLL | Yes | A | 150 000 | Untreated | No | Mutated | Normal karyotype |
| BL24 | CLL | Yes | C | 152 900 | Untreated | Yes | Mutated | del13q, del11q |
| Blood samples from idelalisib-treated patients | ||||||||
| BL25 | CLL | Yes | B | 7 800 | RF, R-Benda | Yes | Unmutated | t(4;11) |
| BL26 | CLL | Yes | B | 21 300 | RFC, R-Benda | Yes | Unmutated | del(11q) |
| BL27 | CLL | Yes | B | 8 500 | CLB, R-Benda | Yes | Unmutated | del(5q), del(6q), del(13q), complex karyotype |
| BL28 | CLL | No | A | 100 000 | RFC, R-Benda | Yes | Unmutated | del(17p), complex karyotype |
| BL29 | CLL | Yes | C | 110 000 | FC, R-Benda | Yes | Mutated | tri12 |
| BL30 | CLL | Yes | C | 250 000 | RF, R-Benda | Yes | Unmutated | Normal karyotype |
| LN biopsy | ||||||||
| LN01 | SLL | No | B | 2 000 | R-CLB | Yes | NA | NA |
| LN02 | SLL | No | A | 1 200 | Untreated | No | NA | NA |
| LN03 | SLL | No | A | 2 000 | Untreated | No | NA | NA |
| LN04 | SLL | No | A | 1 400 | Untreated | No | NA | NA |
| LN05 | SLL | No | C | 2 900 | Untreated | Yes | NA | NA |
| LN06 | SLL | No | C | 1 800 | Untreated | Yes | NA | NA |
| LN07 | SLL | No | B | 4 000 | Untreated | No | NA | NA |
| LN08 | SLL | No | C | 4 000 | RCD | Yes | NA | NA |
| LN09 | CLL | No | A | 7 500 | Untreated | No | NA | NA |
| LN10 | CLL | No | C | 95 000 | RFC | Yes | Mutated | t(14;18) |
| LN11 | CLL | No | A | 35 000 | Untreated | No | NA | NA |
| LN12 | CLL | No | B | 20 000 | CLB | NA | NA | Normal karyotype |
| LN13 | CLL | No | A | 300 000 | CLB | Yes | NA | NA |
| LN14 | CLL | No | A | 11 200 | Untreated | No | Mutated | del(11q) |
| LN15 | CLL | No | C | 7 650 | Pento-RC | Yes | Unmutated | del(17p) |
| LN16 | CLL | No | A | 18 100 | Untreated | No | NA | NA |
| LN17 | CLL | No | A | 90 000 | Untreated | No | NA | NA |
| LN18 | CLL | NA | NA | NA | NA | Na | NA | NA |
| LN19 | CLL | Yes | B | 60 000 | Untreated | Yes | Unmutated | del(11q) |
| LN20 | CLL | Yes | B | 20 000 | CLB, R-mini-CHVP | Yes | NA | del(13q), del(11q) |
| LN21 | CLL | Yes | C | 50 000 | CLB | Yes | Unmutated | del(17p) |
| LN22 | CLL | Yes | C | 138 000 | RFC | Yes | Mutated | Normal karyotype |
| LN23 | CLL | Yes | B | 62 000 | Mabcampath | Yes | Unmutated | del(11q), del(17p), complex karyotype |
| LN24 | CLL | Yes | B | 95 000 | RFC | Yes | Unmutated | del(11q) |
| LN25 | CLL | Yes | A | 6 700 | R-CVP | Yes | Mutated | tri12, tri18, del(13q) |
| LN26 | CLL | Yes | C | 61 000 | R-Benda | Yes | Unmutated | del(11q) |
| LN27 | CLL | Yes | B | 13 300 | Mini-CHVP | Yes | NA | del(11q), complex karyotype |
| LN28 | CLL | Yes | B | 16 000 | Untreated | Yes | Unmutated | del11q |
| Patient no. . | CLL/ SLL . | Bulky . | Binet stage . | Circulating count, cells/mm3 . | Treatments . | Active disease IWCLL 2008 criteria . | IgVH . | Mutations . |
|---|---|---|---|---|---|---|---|---|
| Blood samples from untreated patients | ||||||||
| BL01 | SLL | Yes | B | 3 300 | Untreated | No | Unmutated | tri12 |
| BL02 | CLL | Yes | B | 30 000 | Untreated | No | Unmutated | del(11q), del(13q), del(14q), complex karyotype |
| BL03 | CLL | Yes | B | 22 000 | Untreated | No | Unmutated | del(11q) |
| BL04 | CLL | No | A | 120 000 | Untreated | No | Mutated | t(14;18) |
| BL05 | CLL | No | A | 50 000 | Untreated | No | Mutated | Normal karyotype |
| BL06 | CLL | No | B | 45 000 | Untreated | No | Unmutated | tri12, del(6q), simple karyotype |
| BL07 | CLL | No | A | 106 000 | Untreated | Yes | Unmutated | del(13q) |
| BL08 | CLL | No | A | 130 000 | Untreated | No | Unmutated | Normal karyotype |
| BL09 | CLL | No | A | 21 000 | Untreated | No | Mutated | del(13q), tri12, tri19 |
| BL10 | CLL | No | B | 77 000 | Untreated | No | Mutated | Normal karyotype |
| BL11 | CLL | No | C | 79 860 | Untreated | Yes | Unmutated | t(3;8), del6q |
| BL12 | CLL | No | B | 65 710 | Untreated | No | Mutated | del13q, del11q |
| BL13 | CLL | No | A | 111 710 | Untreated | No | NA | NA |
| BL14 | CLL | No | C | 93 400 | Untreated | Yes | Unmutated | del1q, del6q, del13q |
| BL15 | CLL | Yes | C | 52 000 | Untreated | Yes | Unmutated | Normal karyotype |
| BL16 | CLL | Yes | C | 141 000 | Untreated | Yes | Mutated | del(13q) |
| BL17 | CLL | Yes | B | 82 700 | Untreated | No | Unmutated | del(17p), tri12, del(13q) |
| BL18 | CLL | Yes | C | 177 000 | Untreated | Yes | Mutated | NA |
| BL19 | CLL | Yes | C | 40 000 | Untreated | Yes | Mutated | del(13q) |
| BL20 | CLL | Yes | C | 140 000 | Untreated | Yes | Mutated | del(13q), del(17p), complex karyotype |
| BL21 | CLL | Yes | B | 80 000 | Untreated | No | Mutated | del(11q) |
| BL22 | CLL | Yes | B | 76 300 | Untreated | No | Mutated | tri12 |
| BL23 | CLL | Yes | A | 150 000 | Untreated | No | Mutated | Normal karyotype |
| BL24 | CLL | Yes | C | 152 900 | Untreated | Yes | Mutated | del13q, del11q |
| Blood samples from idelalisib-treated patients | ||||||||
| BL25 | CLL | Yes | B | 7 800 | RF, R-Benda | Yes | Unmutated | t(4;11) |
| BL26 | CLL | Yes | B | 21 300 | RFC, R-Benda | Yes | Unmutated | del(11q) |
| BL27 | CLL | Yes | B | 8 500 | CLB, R-Benda | Yes | Unmutated | del(5q), del(6q), del(13q), complex karyotype |
| BL28 | CLL | No | A | 100 000 | RFC, R-Benda | Yes | Unmutated | del(17p), complex karyotype |
| BL29 | CLL | Yes | C | 110 000 | FC, R-Benda | Yes | Mutated | tri12 |
| BL30 | CLL | Yes | C | 250 000 | RF, R-Benda | Yes | Unmutated | Normal karyotype |
| LN biopsy | ||||||||
| LN01 | SLL | No | B | 2 000 | R-CLB | Yes | NA | NA |
| LN02 | SLL | No | A | 1 200 | Untreated | No | NA | NA |
| LN03 | SLL | No | A | 2 000 | Untreated | No | NA | NA |
| LN04 | SLL | No | A | 1 400 | Untreated | No | NA | NA |
| LN05 | SLL | No | C | 2 900 | Untreated | Yes | NA | NA |
| LN06 | SLL | No | C | 1 800 | Untreated | Yes | NA | NA |
| LN07 | SLL | No | B | 4 000 | Untreated | No | NA | NA |
| LN08 | SLL | No | C | 4 000 | RCD | Yes | NA | NA |
| LN09 | CLL | No | A | 7 500 | Untreated | No | NA | NA |
| LN10 | CLL | No | C | 95 000 | RFC | Yes | Mutated | t(14;18) |
| LN11 | CLL | No | A | 35 000 | Untreated | No | NA | NA |
| LN12 | CLL | No | B | 20 000 | CLB | NA | NA | Normal karyotype |
| LN13 | CLL | No | A | 300 000 | CLB | Yes | NA | NA |
| LN14 | CLL | No | A | 11 200 | Untreated | No | Mutated | del(11q) |
| LN15 | CLL | No | C | 7 650 | Pento-RC | Yes | Unmutated | del(17p) |
| LN16 | CLL | No | A | 18 100 | Untreated | No | NA | NA |
| LN17 | CLL | No | A | 90 000 | Untreated | No | NA | NA |
| LN18 | CLL | NA | NA | NA | NA | Na | NA | NA |
| LN19 | CLL | Yes | B | 60 000 | Untreated | Yes | Unmutated | del(11q) |
| LN20 | CLL | Yes | B | 20 000 | CLB, R-mini-CHVP | Yes | NA | del(13q), del(11q) |
| LN21 | CLL | Yes | C | 50 000 | CLB | Yes | Unmutated | del(17p) |
| LN22 | CLL | Yes | C | 138 000 | RFC | Yes | Mutated | Normal karyotype |
| LN23 | CLL | Yes | B | 62 000 | Mabcampath | Yes | Unmutated | del(11q), del(17p), complex karyotype |
| LN24 | CLL | Yes | B | 95 000 | RFC | Yes | Unmutated | del(11q) |
| LN25 | CLL | Yes | A | 6 700 | R-CVP | Yes | Mutated | tri12, tri18, del(13q) |
| LN26 | CLL | Yes | C | 61 000 | R-Benda | Yes | Unmutated | del(11q) |
| LN27 | CLL | Yes | B | 13 300 | Mini-CHVP | Yes | NA | del(11q), complex karyotype |
| LN28 | CLL | Yes | B | 16 000 | Untreated | Yes | Unmutated | del11q |
Benda, bendamustine; CLB, chlorambucil; CVP, cyclophosphamide; del, deletion; FC, fludarabine, cyclophosphamide; IgVH, immunoglobulin variable region heavy chain; IWCLL, International Workshop on Chronic Lymphocytic Leukaemia; mini-CHVP, cyclophosphamide, doxorubicin, vindesine, prednisone; NA, not available; Pento, pentostatine; R, rituximab; RC, rituximab, cyclophosphamide; RCD, rituximab, cyclophosphamide, dexamethasone; RF, rituximab, fludarabine; RFC, rituximab, fludarabine, cyclophosphamide; t, translocation; tri, trisomy.